[go: up one dir, main page]

GB2246779B - Tumour-associated protease inhibitors targeted to tumour cells - Google Patents

Tumour-associated protease inhibitors targeted to tumour cells

Info

Publication number
GB2246779B
GB2246779B GB9017083A GB9017083A GB2246779B GB 2246779 B GB2246779 B GB 2246779B GB 9017083 A GB9017083 A GB 9017083A GB 9017083 A GB9017083 A GB 9017083A GB 2246779 B GB2246779 B GB 2246779B
Authority
GB
United Kingdom
Prior art keywords
tumour
protease inhibitors
associated protease
inhibitors targeted
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB9017083A
Other versions
GB2246779A (en
GB9017083D0 (en
Inventor
David James Ballance
Michael George Courtney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Priority to GB9017083A priority Critical patent/GB2246779B/en
Publication of GB9017083D0 publication Critical patent/GB9017083D0/en
Priority to PCT/GB1991/001322 priority patent/WO1992002553A1/en
Priority to AU83185/91A priority patent/AU8318591A/en
Publication of GB2246779A publication Critical patent/GB2246779A/en
Application granted granted Critical
Publication of GB2246779B publication Critical patent/GB2246779B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
GB9017083A 1990-08-03 1990-08-03 Tumour-associated protease inhibitors targeted to tumour cells Expired - Lifetime GB2246779B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9017083A GB2246779B (en) 1990-08-03 1990-08-03 Tumour-associated protease inhibitors targeted to tumour cells
PCT/GB1991/001322 WO1992002553A1 (en) 1990-08-03 1991-08-02 Tumor cell binding molecule with protease inhibiting region
AU83185/91A AU8318591A (en) 1990-08-03 1991-08-02 Tumor cell binding molecule with protease inhibiting region

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9017083A GB2246779B (en) 1990-08-03 1990-08-03 Tumour-associated protease inhibitors targeted to tumour cells

Publications (3)

Publication Number Publication Date
GB9017083D0 GB9017083D0 (en) 1990-09-19
GB2246779A GB2246779A (en) 1992-02-12
GB2246779B true GB2246779B (en) 1994-08-17

Family

ID=10680139

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9017083A Expired - Lifetime GB2246779B (en) 1990-08-03 1990-08-03 Tumour-associated protease inhibitors targeted to tumour cells

Country Status (3)

Country Link
AU (1) AU8318591A (en)
GB (1) GB2246779B (en)
WO (1) WO1992002553A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1013285A3 (en) * 1989-04-07 2004-05-19 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Urokinase-type plasminogen activator receptor
US6120765A (en) * 1993-04-02 2000-09-19 Shiseido Co. Ltd. Urokinase plasminogen activator fragments
FI955720A7 (en) * 1993-05-28 1995-11-27 Chiron Corp Peptide inhibitors of urokinase receptor activity
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) * 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997025422A1 (en) 1996-01-08 1997-07-17 Nissin Food Products Co., Ltd. Cancerous metastasis inhibitor
NZ500656A (en) * 1997-05-12 2001-11-30 Tno Vector containing a nucleic acid insertion expressing a hybrid polypeptide with a protease inhibitor domain and a receptor binding domain
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
US6077508A (en) * 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE60138403D1 (en) 2000-09-26 2009-05-28 Crucell Holland Bv ADENOVIRAL VECTORS FOR THE TRANSFER OF GENES IN CELLS OF THE SKELETAL MUSCULATORY OR MYOBLAST
MXPA04008891A (en) 2002-04-25 2004-11-26 Crucell Holland Bv Means and methods for the production of adenovirus vectors.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044167A2 (en) * 1980-07-14 1982-01-20 The Regents Of The University Of California Antibody targeted cytotoxic agent
EP0122132A2 (en) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Anti-tumour substance
EP0383599A2 (en) * 1989-02-17 1990-08-22 Merck & Co. Inc. Protein anti-cancer agent
WO1990012091A1 (en) * 1989-04-07 1990-10-18 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623113B2 (en) * 1986-01-31 1994-03-30 浩 前田 Cancerous breast / ascites retention inhibitor
WO1991000912A1 (en) * 1989-07-07 1991-01-24 Massachusetts Institute Of Technology Production and use of hybrid protease inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0044167A2 (en) * 1980-07-14 1982-01-20 The Regents Of The University Of California Antibody targeted cytotoxic agent
EP0122132A2 (en) * 1983-04-08 1984-10-17 Kureha Kagaku Kogyo Kabushiki Kaisha Anti-tumour substance
EP0383599A2 (en) * 1989-02-17 1990-08-22 Merck & Co. Inc. Protein anti-cancer agent
WO1990012091A1 (en) * 1989-04-07 1990-10-18 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Biochemistry International,Vol 19, No.2,1989, pages 313-323 *
BLOOD, Vol.74, 1989, pages 1396-1402. *
CELL, Vol.52, No.3, 1988, pages 321-328. *
Europ.J.Cancer,Vol 14,1978,pages 23-31 *
J.BIOL.CHEM., Vol.62, No.10, 1987, pages 4437-4440. *
J.IMMUNOL., Vol.143, 1989, pages 2634-2639. *
J.Natl.Cancer Inst.,Vol. 74, No.5, 1985,pages 1031-1035 *
PROC. NATL. ACAD. SCI.USA, Vol.87, pages 2230-2234, 1990. *

Also Published As

Publication number Publication date
GB2246779A (en) 1992-02-12
WO1992002553A1 (en) 1992-02-20
GB9017083D0 (en) 1990-09-19
AU8318591A (en) 1992-03-02

Similar Documents

Publication Publication Date Title
GB2246779B (en) Tumour-associated protease inhibitors targeted to tumour cells
DE3377497D1 (en) Enzyme inhibitors
ZA917096B (en) Enzyme inhibitors
GB8518738D0 (en) Power source
EP0252057A3 (en) Serine protease inhibitors
IL77226A (en) Serine protease inhibitors
DE3571129D1 (en) Protease inhibitors
ZA884838B (en) Dopamine-beta-hydroxylase inhibitors
ZA883851B (en) Dopamine-beta-hydroxylase inhibitors
ATA163887A (en) MOBILE CRUSHING PLANT
PT83076B (en) Dopamine-beta-hydroxylase inhibitors
PT83628A (en) Dopamine-beta-hydroxylase inhibitors
ZA889709B (en) Dopamine-beta-hydroxylase inhibitors
GB8816838D0 (en) Power amplifying arrangement
GB8423152D0 (en) Comminutor devices
PT86513A (en) Dopamine-beta-hydroxylase inhibitors
ZA882100B (en) Dopamine-beta-hydroxylase inhibitors
GB2139032B (en) Low power consumption power amplifier
PT83626A (en) Dopamine-beta-hydroxylase inhibitors
GB8722304D0 (en) Grinding peat coal &c
AU9107191A (en) Targetting ige effector cells to tumor cells
GB9009950D0 (en) Medium supplement for the grouth of hybridoma cells
EP0185908A3 (en) High frequency energy source
GB9208800D0 (en) Power amplifiers
PT81973A (en) Dopamine-beta-hydroxylase inhibitors

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20100802